Interest in therapies for psoriatic arthritis (PsA) has increased in response to recognition that many patients remain undiagnosed and are inadequately treated. In 2020, advances in PsA treatments have included phase III trials of an IL-23 inhibitor, head-to-head trials of IL-17 inhibition against TNF inhibition and updated EULAR treatment guidelines.
Key advances
-
Updated EULAR treatment recommendations for psoriatic arthritis (PsA) include newly approved medications, recognize the need for treatment tailored to the individual and encourage targets of remission or low disease activity2.
-
Guselkumab, the first of a new class of drugs that inhibit the p19 subunit of IL-23, was approved for PsA on the basis of results from two phase III clinical trials3,4.
-
Head-to-head trials of IL-17 inhibition against TNF inhibition confirmed similar efficacy of both therapies in musculoskeletal domains of PsA and superior efficacy of IL-17 inhibition in the psoriasis domain5,6.
This is a preview of subscription content, log in via an institution to check access.
References
Ritchlin, C. T., Colbert, R. A. & Gladman, D. D. Psoriatic arthritis. N. Engl. J. Med. 376, 957–970 (2017).
Gossec, L. et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann. Rheum. Dis. 79, 700–712 (2020).
Deodhar, A. et al. Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFalpha inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet 395, 1115–1125 (2020).
Mease, P. J. et al. Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet 395, 1126–1136 (2020).
McInnes, I. B. et al. Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial. Lancet 395, 1496–1505 (2020).
Smolen, J. S. et al. Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naive to biological disease-modifying antirheumatic drug: final results by week 52. Ann. Rheum. Dis. 79, 1310–1319 (2020).
Nguyen, C. et al. Pathophysiology and inhibition of IL-23 signaling in psoriatic arthritis: A molecular insight. Clin. Immunol. 206, 15–22 (2019).
Reich, K. et al. Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials. J. Am. Acad. Dermatol. 82, 936–945 (2020).
Mease, P. J. et al. A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naive patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. Ann. Rheum. Dis. 79, 123–131 (2020).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
P.M. declares that he has received research grants, consultation fees and/or speaker honoraria from AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Janssen, Novartis, Pfizer, SUN Pharma and UCB.
Rights and permissions
About this article
Cite this article
Mease, P.J. New treatments for PsA meet targeted therapy goals. Nat Rev Rheumatol 17, 77–78 (2021). https://doi.org/10.1038/s41584-020-00561-3
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41584-020-00561-3
- Springer Nature Limited